Roth Capital raised the firm’s price target on Sanuwave Health (SNWV) to $54 from $49 and keeps a Buy rating on the shares after the company reported “strong” Q2 results and reiterated its FY25 revenue forecast of $48M-$50M. The firm’s new $15.2M FY25 AEBITDA estimate is up from $14.2M previously, the analyst noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNWV: